NIKKEI 225
27,819.33 -180.63 (-0.65%) HANG SENG
19,610.84 -392.60 (-1.96%) CRUDE OIL
91.81 +1.31 (+1.45%) GOLD FUTURES
1,806.00 -6.30 (-0.35%) DOW
33,192.68 +418.27 (+1.28%) BTC-GBP
19,291.44 +336.24 (+1.77%)
NVAX Jan 2024 175.000 call
| Previous close | 3.0500 |
| Open | 3.4000 |
| Bid | 3.1500 |
| Ask | 3.7000 |
| Strike | 175.00 |
| Expiry date | 2024-01-19 |
| Day's range | 2.5900 - 3.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 23 |
- Motley Fool
1 Reason to Sell Novavax Stock, and 1 Reason to Buy
This year hasn't been an easy one for Novavax (NASDAQ: NVAX) investors. After a series of stumbles culminating in its disastrous earnings report on Aug. 8, its shares are down by 60% so far in 2022. And with management slashing its full-year revenue guidance by roughly half, there isn't much hope for smoother sailing for at least a few quarters.
- Motley Fool
Nasdaq Bear Market: 3 Remarkable Growth Stocks That Can Double Your Money by 2026
A more than 30% peak decline in the Nasdaq Composite is allowing investors to buy these phenomenal stocks at bargain-basement prices.
- Bloomberg
Novavax Rout Extends 87% From Peak Amid Covid-Shot Setbacks
(Bloomberg) -- The selloff in Novavax Inc. shares deepened on Tuesday, to erase $17 billion in market value from last year’s record high, after the Covid-19 vaccine maker slashed its revenue guidance.Most Read from BloombergMusk Sells $6.9 Billion of Tesla to Avoid Twitter Fire SaleUK Plans for Blackouts in January in Emergency Energy PlanTrump Under Intense Legal Scrutiny After FBI Searches Mar-a-LagoRussia Is Scouring the Globe for Weapons to Use Against UkraineTrump Search Was Unprecedented,
